{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:32:57Z","timestamp":1791016377105,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.ahj.2006.04.012","type":"journal-article","created":{"date-parts":[[2006,9,23]],"date-time":"2006-09-23T07:29:02Z","timestamp":1158996542000},"page":"627-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":274,"title":["Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)"],"prefix":"10.1016","volume":"152","author":[{"given":"Stephen D.","family":"Wiviott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott M.","family":"Antman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Riesmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govinda","family":"Weerakkody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Warmke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn H.","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2006.04.012_bib1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ehj.2003.10.013","article-title":"Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology","volume":"25","author":"Patrono","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2006.04.012_bib2","first-page":"e116","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.04.012_bib3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.04.012_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ajh.2830440415","article-title":"Bone marrow aplasia associated with ticlopidine therapy","volume":"44","author":"Elias","year":"1993","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ahj.2006.04.012_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2006.04.012_bib6","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2006.04.012_bib7","first-page":"374","article-title":"Optimal duration of pretreatment with clopidogrel prior to PCI: data from the Credo Trial","volume":"108-IV","author":"Steinhubl","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.04.012_bib8","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0002-9149(03)00163-2","article-title":"Durability of platelet inhibition by clopidogrel","volume":"91","author":"Gurbel","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2006.04.012_bib9","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.04.012_bib10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-0037-1613462","article-title":"Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement","volume":"89","author":"Muller","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2006.04.012_bib11","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1161\/01.CIR.0000134701.40946.30","article-title":"Clopidogrel resistance: a new chapter in a fast-moving story","volume":"109","author":"Wiviott","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.04.012_bib12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jacc.2004.09.067","article-title":"Variability in platelet responsiveness to clopidogrel among 544 individuals","volume":"45","author":"Serebruany","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2006.04.012_bib13","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.04.012_bib14","first-page":"295","article-title":"Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation","volume":"59","author":"Barragan","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2006.04.012_bib15","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/sj.bjp.0703237","article-title":"The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties","volume":"129","author":"Sugidachi","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ahj.2006.04.012_bib16","first-page":"87A","article-title":"Superior responder rate for inhibition of platelet aggregation with a 60 mg loading dose of prasugrel (CS-747, LY640315) compared with a 300 mg loading dose of clopidogrel","volume":"45","author":"Brandt","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"3 Suppl A","key":"10.1016\/j.ahj.2006.04.012_bib17","first-page":"87A","article-title":"A comparison of prasugrel (CS-747, LY640315) with clopidogrel on platelet function in healthy male volunteers","volume":"45","author":"Asai","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2006.04.012_bib18","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","article-title":"Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease","volume":"27","author":"Jernberg","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2006.04.012_bib19","unstructured":"Ogawa T, Sugidachi A, Isobe T, et al. Greater in Vivo Potency of prasugrel (CS-747, LY640315) vs. Clopidogrel Is Not Explained by Differential Activity of Active Metabolites. European Society of Cardiology, 2005."},{"key":"10.1016\/j.ahj.2006.04.012_bib20","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","article-title":"Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)\u2013TIMI 26 trial","volume":"111","author":"Wiviott","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.04.012_bib21","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non\u2013ST elevation MI: a method for prognostication and therapeutic decision making","volume":"284","author":"Antman","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2006.04.012_bib22","first-page":"1","article-title":"CS-747, a new platelet ADP receptor antagonist","author":"Asai","year":"1999","journal-title":"Annual Report Sankyo Research Laboratory"},{"key":"10.1016\/j.ahj.2006.04.012_bib23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/s-2005-869524","article-title":"Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity","volume":"31","author":"Niitsu","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ahj.2006.04.012_bib24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa031859","article-title":"A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel","volume":"350","author":"Kastrati","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2006.04.012_bib25","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1161\/01.CIR.0000137972.74120.12","article-title":"Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy","volume":"110","author":"Kastrati","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.04.012_bib26","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jacc.2005.01.030","article-title":"The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting","volume":"45","author":"Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2006.04.012_bib27","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/01.CIR.0000157138.02645.11","article-title":"Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study","volume":"111","author":"Gurbel","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.04.012_bib28","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1161\/01.CIR.0000161383.06692.D4","volume":"111","author":"Patti","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.04.012_bib29","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/S0735-1097(01)01702-8","volume":"38","author":"Cannon","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2006.04.012_bib30","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1053\/euhj.2000.2474","article-title":"The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease","volume":"21","author":"Mehta","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2006.04.012_bib31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2006.04.012_bib32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2307\/2530109","article-title":"Predictive probability early termination plans for phase II clinical trials","volume":"35","author":"Herson","year":"1979","journal-title":"Biometrics"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870306003486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870306003486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:28:05Z","timestamp":1757568485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870306003486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0002870306003486"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2006.04.012","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2006.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}